Fig. 1: High SREBP-1 level correlates to poor prognosis of advanced HCC patients who received Sorafenib treatment. | Cell Death & Disease

Fig. 1: High SREBP-1 level correlates to poor prognosis of advanced HCC patients who received Sorafenib treatment.

From: SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity

Fig. 1

a Patients were divided into SREBP-1 high and SREBP-1 low groups based on the expression level. b PCR results from ten representative specimens (five high and five low). c Overall survival (OS) comparison of HCC patients in the SREBP-1 high group and the SREBP-1 low group. d Time to progress (TTP) of HCC patients in the SREBP-1 high group and the SREBP-1 low group. e, f The relative SREBP-1 expressions at both mRNA (e) and protein levels (f) in different cell lines. Survival analysis was performed by the Kaplan–Meier method and compared by the log-rank test. Paired samples were tested by the paired-sample t-test. Significant: *p < 0.05 in all figures

Back to article page